Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.13253 http://scihub22266oqcxt.onion/10.18632/oncotarget.13253 C5386673!5386673!27835912     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2017 ; 8 (12): 19125-36 Nephropedia Template TP {{tp|p=27835912|t=2017. A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer |pdf=|usr=}}{{27835912}} gab.com Text A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27835912 #FOAvip This study compared the short-term efficacies of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) through pair-wise and network meta-analyses (NMA). Randomized controlled trials (RCTs) identified in a comprehensive online literature search met our inclusion criteria. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cumulative ranking curves (SUCRA) across the different treatment regimens. Twelve eligible RCTs were finally included, involving eight regimens (Paclitaxel + Carboplatin [PC], Gemcitabine + Carboplatin [GC], Carboplatin, Pegylated Liposomal Doxorubicin + Carboplatin [PLD + Carboplatin], Paclitaxel, Paclitaxel + Carboplatin + Topotecan [PC + Topotecan], Paclitaxel + Carboplatin + Epirubicin [PC + Epirubicin] and Docetaxel + Carboplatin [DC]). The NMA results revealed that in terms of overall response rate (ORR) and disease control rate (DCR), PC (ORR: OR=2.59, 95%CI=1.20?6.22; DCR: OR=2.58, 95%CI=1.05?6.82) and GC (ORR: OR=2.08, 95%CI=1.08?4.37; DCR: OR=2.43, 95%CI=1.07?5.80) were more effective against AOC than Carboplatin alone. Similarly, PC (OR=0.21, 95%CI=0.05?0.69), GC (OR=0.31, 95%CI=0.09?0.90) and PLD + Carboplatin (OR=0.22, 95%CI=0.04?0.92) slowed disease progression better than Carboplatin alone. We also found that PC was more efficacious against AOC than Carboplatin or Paclitaxel single-agent chemotherapy. Combination chemotherapy is thus recommended for AOC, and should guide subsequent drug development and treatment strategies. Twit Text FOAVip A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27835912 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27835912 #FOAvip English Wikipedia <ref>{{Cite pmid|27835912}}</ref> A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer #MMPMID27835912 Jiang XP; Rui XH; Guo CX; Huang YQ; Li Q; Xu Y Oncotarget 2017[Mar]; 8 (12): 19125-36 PMID27835912show ga This study compared the short-term efficacies of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) through pair-wise and network meta-analyses (NMA). Randomized controlled trials (RCTs) identified in a comprehensive online literature search met our inclusion criteria. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cumulative ranking curves (SUCRA) across the different treatment regimens. Twelve eligible RCTs were finally included, involving eight regimens (Paclitaxel + Carboplatin [PC], Gemcitabine + Carboplatin [GC], Carboplatin, Pegylated Liposomal Doxorubicin + Carboplatin [PLD + Carboplatin], Paclitaxel, Paclitaxel + Carboplatin + Topotecan [PC + Topotecan], Paclitaxel + Carboplatin + Epirubicin [PC + Epirubicin] and Docetaxel + Carboplatin [DC]). The NMA results revealed that in terms of overall response rate (ORR) and disease control rate (DCR), PC (ORR: OR=2.59, 95%CI=1.20?6.22; DCR: OR=2.58, 95%CI=1.05?6.82) and GC (ORR: OR=2.08, 95%CI=1.08?4.37; DCR: OR=2.43, 95%CI=1.07?5.80) were more effective against AOC than Carboplatin alone. Similarly, PC (OR=0.21, 95%CI=0.05?0.69), GC (OR=0.31, 95%CI=0.09?0.90) and PLD + Carboplatin (OR=0.22, 95%CI=0.04?0.92) slowed disease progression better than Carboplatin alone. We also found that PC was more efficacious against AOC than Carboplatin or Paclitaxel single-agent chemotherapy. Combination chemotherapy is thus recommended for AOC, and should guide subsequent drug development and treatment strategies. äA network meta-analysis of eight chemotherapy regimens for treatment o(epmc).pdf DeepDyve Pubget Overpricing